In vitro and in vivo experimental models for drug screening and development for Chagas disease.
about
Translational challenges of animal models in Chagas disease drug development: a reviewNovel amidines and analogues as promising agents against intracellular parasites: a systematic reviewRevisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?Trypanocidal activity of marine natural productsA new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imagingIn vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infectionHigh throughput screening for anti-Trypanosoma cruzi drug discoveryAptamer-based detection of disease biomarkers in mouse models for chagas drug discoveryQuality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic ReviewLinalool, a Piper aduncum essential oil component, has selective activity against Trypanosoma cruzi trypomastigote forms at 4°CDiversity patterns, ecology and biological activities of fungal communities associated with the endemic macroalgae across the Antarctic peninsula.Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.Ergosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria.In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite deathActivities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo.Bioactive endophytic fungi isolated from Caesalpinia echinata Lam. (Brazilwood) and identification of beauvericin as a trypanocidal metabolite from Fusarium sp.Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1.Diversity and bioprospection of fungal community present in oligotrophic soil of continental Antarctica.Phenotypic Features of Circulating Leukocytes from Non-human Primates Naturally Infected with Trypanosoma cruzi Resemble the Major Immunological Findings Observed in Human Chagas Disease.Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.Advances in Chagas disease drug development: 2009-2010In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.Polyamine depletion inhibits the autophagic response modulating Trypanosoma cruzi infectivityPhenotypic Screening In Vitro of Novel Aromatic Amidines against Trypanosoma cruzi.In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.Chagas disease drug discovery: toward a new era.In vitro activity of 1,3-bisaryloxypropanamines against Trypanosoma cruzi-infected L929 cultures.Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti-Trypanosomal Lychnopholide.Biological activities of ophiobolin K and 6-epi-ophiobolin K produced by the endophytic fungus Aspergillus calidoustus.Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.Novel naphthoquinone derivatives and evaluation of their trypanocidal and leishmanicidal activities.Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.Fungi associated with rocks of the Atacama Desert: taxonomy, distribution, diversity, ecology and bioprospection for bioactive compounds.Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.
P2860
Q26796451-B1C22119-A16F-4409-A017-AC2DB6DC12AFQ26825025-5B0E078D-A456-4EE8-A3EB-B9C823DC295FQ26859040-16F2FCED-C196-4C97-ABA5-DAFF30974808Q27008593-AA3D9BC1-8B9B-4D72-9A60-AE3788E25E4DQ27011506-AF7DB999-86ED-4AC2-BFDE-B4D7BCC08A5EQ28479017-3A3E6A6C-0BBE-48DF-84AF-63DB85AC9148Q28542489-B04880E6-58D6-49FD-83A0-BEECB688519EQ28542996-3A98B984-5C7A-4811-BF31-6271AF20A14AQ28551079-D3ADC5AE-EE08-4268-BFA2-C145178C248FQ28817421-59A8CBA4-EE41-43C8-9FAD-E30F9811AFE7Q30752762-3F279C53-2BEF-4A06-AAB4-E3A034FE8175Q33713176-2AAF4859-5340-4ED9-AD6D-62638E5C010FQ33743694-8CA67539-D329-4DA9-87A3-C4159F727FD9Q33798498-A3EE6E59-AFCB-4E9A-AC48-FBC7059FB3E9Q33918063-8E3CA3A8-AC11-45F7-A82E-81E1038889BEQ34299137-51B9D50C-A35C-4D3E-89FB-34180CA8F4FAQ34363646-715812D8-EE2A-40A7-8816-B07FB538E895Q35210859-182D4625-28F1-44C8-9472-A57D1D9CD1FFQ35210866-BD7A834D-E228-4CA1-8A63-97607E3FBD46Q35367533-F2580289-FE41-4ECE-87D5-2D0FEDD18915Q35385420-15FE1BE5-5B61-43C7-BE23-66D76A20A9A2Q35586912-09574591-138D-4489-9195-8EC5A56AECF1Q35903600-35E55286-4CF7-431E-97D2-854204E095BBQ36290550-77AF6978-2B2C-42CF-9AA8-04395FD76B9EQ36702159-3CC7C9CD-89A2-43A8-A69D-25ACDC90498EQ36730126-7309558F-896E-4637-B01D-0980DB94AFF7Q37043029-1AC07D5D-F06E-455D-8DF5-2259D052410DQ37120187-1C0A0240-CB64-4190-B824-19494F8C5343Q37124209-215E0A6F-F770-4945-8627-EE6F8B2143D3Q37342932-9E0E013B-3658-4A5E-BE04-33BA1BDA29EFQ38253281-C7A1A393-D7AC-4420-954D-2A35BAE0245BQ38865455-7293CCDC-18B3-455F-9C55-35304BAE2D6CQ38871527-B0FF6354-59FC-4827-B72A-E83415E5478BQ38894679-4DC3D299-D8C2-4D38-BBBC-3F382D14D8F3Q38927054-DADD3EC4-8AEA-4908-843B-4D65735154E6Q38938717-F75EB4F6-75A1-4203-9D5D-C879573E95F7Q38942718-E1B8A347-0551-4DA1-B4A0-86B749232775Q39003990-32DA5BC0-A0DB-4EF0-B639-18B51E4B587BQ39028299-C121C4FA-0632-4274-A742-AA9A5FC88031Q39033607-89185073-989C-4900-A904-130930528068
P2860
In vitro and in vivo experimental models for drug screening and development for Chagas disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@en
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@nl
type
label
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@en
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@nl
prefLabel
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@en
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@nl
P2093
P2860
P1476
In vitro and in vivo experimen ...... evelopment for Chagas disease.
@en
P2093
Alvaro José Romanha
André Talvani
Bernadette Bourdin
Bethania Blum
Bianca Olivieri
Carlos Zani
Carmenza Spadafora
Egler Chiari
Eric Chatelain
Gabriela Chaves
P2860
P304
P356
10.1590/S0074-02762010000200022
P50
P577
2010-03-01T00:00:00Z